Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment
Piper Sandler has started coverage of Arvinas (ARVN) with a buy rating saying that Sanofi (SNY) recent discontinuation of amcenestrant for breast cancer will benefit the biotech.The…
Arvinas a buy at Piper Sandler following failure of Sanofi breast cancer treatment
Piper Sandler has started coverage of Arvinas (ARVN) with a buy rating saying that Sanofi (SNY) recent discontinuation of amcenestrant for breast cancer will benefit the biotech.The…